ZYUS Secures $200K in Third Tranche of Secured Loan Financing
Event summary
- ZYUS Life Sciences closed a third tranche of secured loan financing on June 17, 2026, raising CAD$200,000, bringing the total to CAD$645,000.
- The loan is secured by a general security agreement, subject to TSX Venture Exchange approval, with a 12% annual interest rate.
- Insiders, including a board member, participated with CAD$100,000, constituting a related party transaction under MI 61-101.
- Proceeds will be used for general working capital purposes.
The big picture
ZYUS's secured loan financing reflects the challenges faced by clinical-stage biopharmaceutical companies in securing non-dilutive funding. The involvement of insiders highlights the strategic importance of maintaining liquidity for working capital amid regulatory and market uncertainties. The loan's structure, including the 12% interest rate and six-month maturity, underscores the high-cost nature of such financing in the current environment.
What we're watching
- Debt Sustainability
- Whether ZYUS can secure additional tranches to reach the CAD$2 million aggregate size and sustain its operations.
- Regulatory Approval
- The pace at which TSX Venture Exchange approves the secured loan, given the general security agreement.
- Execution Risk
- How ZYUS will allocate the proceeds to advance its non-opioid drug candidates and manage the 12% interest rate.